LT3484865T - Somatostatino moduliatoriai ir jų panaudojimas - Google Patents

Somatostatino moduliatoriai ir jų panaudojimas

Info

Publication number
LT3484865T
LT3484865T LTEPPCT/US2017/041694T LTUS2017041694T LT3484865T LT 3484865 T LT3484865 T LT 3484865T LT US2017041694 T LTUS2017041694 T LT US2017041694T LT 3484865 T LT3484865 T LT 3484865T
Authority
LT
Lithuania
Prior art keywords
somatostatin modulators
somatostatin
modulators
Prior art date
Application number
LTEPPCT/US2017/041694T
Other languages
English (en)
Inventor
Jian Zhao
Sangdon Han
Sun Hee Kim
Shimiao Wang
Yunfei Zhu
Original Assignee
Crinetics Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crinetics Pharmaceuticals, Inc. filed Critical Crinetics Pharmaceuticals, Inc.
Publication of LT3484865T publication Critical patent/LT3484865T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
LTEPPCT/US2017/041694T 2016-07-14 2017-07-12 Somatostatino moduliatoriai ir jų panaudojimas LT3484865T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662362493P 2016-07-14 2016-07-14
US201662411338P 2016-10-21 2016-10-21
PCT/US2017/041694 WO2018013676A1 (en) 2016-07-14 2017-07-12 Somatostatin modulators and uses thereof

Publications (1)

Publication Number Publication Date
LT3484865T true LT3484865T (lt) 2022-11-10

Family

ID=60941935

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2017/041694T LT3484865T (lt) 2016-07-14 2017-07-12 Somatostatino moduliatoriai ir jų panaudojimas

Country Status (24)

Country Link
US (7) US9896432B2 (lt)
EP (2) EP4163276A1 (lt)
JP (2) JP6967577B2 (lt)
KR (2) KR20210134838A (lt)
CN (2) CN115557929A (lt)
AU (2) AU2017296392B2 (lt)
CA (1) CA3030423A1 (lt)
DK (1) DK3484865T3 (lt)
ES (1) ES2931472T3 (lt)
HR (1) HRP20221279T1 (lt)
HU (1) HUE060182T2 (lt)
IL (1) IL264178B2 (lt)
LT (1) LT3484865T (lt)
MX (1) MX390120B (lt)
NZ (1) NZ750174A (lt)
PL (1) PL3484865T3 (lt)
PT (1) PT3484865T (lt)
RS (1) RS63776B1 (lt)
SG (1) SG11201900349VA (lt)
SM (1) SMT202200465T1 (lt)
TW (1) TWI789355B (lt)
UA (1) UA125393C2 (lt)
WO (1) WO2018013676A1 (lt)
ZA (1) ZA201900317B (lt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017296392B2 (en) * 2016-07-14 2020-09-24 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
KR20190121404A (ko) * 2017-03-16 2019-10-25 크리네틱스 파마슈티칼스, 인크. 소마토스타틴 조절제 및 이의 용도
EP3658560A4 (en) 2017-07-25 2021-01-06 Crinetics Pharmaceuticals, Inc. SOMATOSTAT IN MODULATORS AND USES THEREOF
MA51625B1 (fr) 2018-01-17 2022-07-29 Crinetics Pharmaceuticals Inc Procédé de production de modulateurs de somatostatine
US11608335B2 (en) 2018-02-12 2023-03-21 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
EP3807248A4 (en) * 2018-05-29 2021-10-27 Council of Scientific and Industrial Research BICYCLIC TOPOISOMERASE I INHIBITOR COMPOUNDS, THEIR PREPARATION AND USE
US10696689B2 (en) 2018-09-18 2020-06-30 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
US12617767B2 (en) 2019-07-17 2026-05-05 Crinetics Pharmaceuticals, Inc. Crystalline forms of somatostatin modulators
TWI841768B (zh) 2019-08-14 2024-05-11 美商克林提克斯醫藥股份有限公司 非肽生長抑制素(somatostatin)5型受體激動劑及其用途
WO2022055880A1 (en) * 2020-09-09 2022-03-17 Crinetics Pharmaceuticals, Inc. Formulations of a somatostatin modulator
WO2022177974A1 (en) 2021-02-17 2022-08-25 Crinetics Pharmaceuticals, Inc. Crystalline forms of a somatostatin modulator
JP2024520274A (ja) * 2021-05-25 2024-05-24 クリネティックス ファーマシューティカルズ，インク． 疾患の治療のためのソマトスタチンモジュレータの使用
EP4378971B1 (en) 2021-09-28 2026-01-28 Denka Company Limited Chloroprene block copolymer, latex, latex composition, and rubber composition
IL314054A (en) * 2022-01-11 2024-09-01 Crinetics Pharmaceuticals Inc Uses of a somatostatin modulator for the treatment of carcinoid syndrome
EP4547654A1 (en) 2022-06-10 2025-05-07 Assia Chemical Industries Ltd. Solid state forms of paltusotine and process for preparation thereof
JP2026511290A (ja) * 2022-10-28 2026-04-13 ベースキャンプ・バイオ・インコーポレイテッド ソマトスタチン受容体２作動薬およびその使用
WO2024129614A1 (en) 2022-12-13 2024-06-20 Crinetics Pharmaceuticals, Inc. Somatostatin subtype-2 receptor (sst2r) targeted therapeutics and uses thereof
EP4687898A1 (en) 2023-03-28 2026-02-11 Crinetics Pharmaceuticals, Inc. Compositions and methods for administering paltusotine to patients with hepatic impairment
TW202523316A (zh) * 2023-11-22 2025-06-16 美商克林提克斯醫藥股份有限公司 生長抑制素亞型3受器（sstr3）激動劑及其用途

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1035154A (en) 1910-05-16 1912-08-13 Ernest G Clark Machine for rectifying perforated music and masters.
FR2802206B1 (fr) 1999-12-14 2005-04-22 Sod Conseils Rech Applic Derives de 4-aminopiperidine et leur utilisation en tant que medicament
EP1451156A4 (en) 2001-11-27 2005-05-25 Merck & Co Inc 4-AMINOCHINOLINVERBINDUNGEN
JP4216196B2 (ja) * 2002-02-04 2009-01-28 エフ．ホフマン−ラ ロシュ アーゲー Ｎｐｙアンタゴニストとしてのキノリン誘導体
WO2005024416A1 (en) 2003-09-05 2005-03-17 Binghe Wang Water soluble boronic acid fluorescent reporter compounds and methods of use thereof
JP2008506695A (ja) * 2004-07-13 2008-03-06 グラクソ　グループ　リミテッド 抗細菌剤
US20060183763A1 (en) 2004-12-31 2006-08-17 Pfizer Inc Novel pyrrolidyl derivatives of heteroaromatic compounds
EP1959948B1 (en) 2005-12-05 2012-07-18 XenoPort, Inc. Levodopa prodrug mesylate, compositions thereof, and uses thereof
JP2009527562A (ja) 2006-02-21 2009-07-30 アムゲン インコーポレイティッド ホスホジエステラーゼ１０阻害剤としてのシンノリン誘導体
WO2007103554A1 (en) 2006-03-08 2007-09-13 Amgen Inc. Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors
US20090258853A1 (en) 2006-03-13 2009-10-15 Brian Eastman Somatostatin Agonists
JP5564045B2 (ja) 2008-09-02 2014-07-30 ノバルティス アーゲー 二環式キナーゼ阻害剤
GB0818241D0 (en) 2008-10-06 2008-11-12 Cancer Res Technology Compounds and their use
WO2012016082A1 (en) 2010-07-30 2012-02-02 Oncotherapy Science, Inc. Quinoline derivatives and melk inhibitors containing the same
AU2012258977A1 (en) 2011-05-23 2014-01-16 Imago Pharmaceuticals, Inc. Inhibitors of LRRK2 kinase activity
US8871756B2 (en) 2011-08-11 2014-10-28 Hoffmann-La Roche Inc. Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease
DE102011113749A1 (de) 2011-09-14 2013-03-14 Aicuris Gmbh & Co. Kg Sulfonsäuresalze Heterocyclylamid-substituiertr Imidazole
US20140228417A1 (en) 2011-10-05 2014-08-14 Mapi Pharma Ltd. Process and intermediates for the preparation of substituted 2-arylthiazole carboxylic acids
JP6299591B2 (ja) * 2012-07-03 2018-03-28 小野薬品工業株式会社 ソマトスタチン受容体作動活性を有する化合物およびその医薬用途
US9309222B2 (en) * 2012-10-16 2016-04-12 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
BR112016007078A2 (pt) * 2013-09-30 2017-12-12 Ono Pharmaceutical Co composto tendo atividade agonística do receptor de somatostatina e uso farmacêutico do mesmo
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
US20170096422A1 (en) 2014-03-24 2017-04-06 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2016049568A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Methods and compositions for inhibition of ras
EP3317278B1 (en) 2015-07-01 2021-04-14 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
HK1255034A1 (zh) 2015-07-01 2019-08-02 Crinetics Pharmaceuticals, Inc. 生长抑素调节剂及其用途
MX2021006804A (es) 2015-12-17 2023-01-13 Merck Patent Gmbh Antagonistas policiclicos del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos en el tratamiento de trastornos inmunitarios.
US10597393B2 (en) 2016-07-07 2020-03-24 Plantex Ltd. Solid state forms of Palbociclib dimesylate
AU2017296392B2 (en) 2016-07-14 2020-09-24 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
MA51625B1 (fr) 2018-01-17 2022-07-29 Crinetics Pharmaceuticals Inc Procédé de production de modulateurs de somatostatine
US10696689B2 (en) 2018-09-18 2020-06-30 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
US12617767B2 (en) 2019-07-17 2026-05-05 Crinetics Pharmaceuticals, Inc. Crystalline forms of somatostatin modulators
WO2022055880A1 (en) 2020-09-09 2022-03-17 Crinetics Pharmaceuticals, Inc. Formulations of a somatostatin modulator

Also Published As

Publication number Publication date
TW201805276A (zh) 2018-02-16
CA3030423A1 (en) 2018-01-18
BR112019000692A2 (pt) 2019-04-24
JP2022028675A (ja) 2022-02-16
US20180016252A1 (en) 2018-01-18
UA125393C2 (uk) 2022-03-02
HRP20221279T1 (hr) 2022-12-23
MX390120B (es) 2025-03-20
US10351547B2 (en) 2019-07-16
JP2019520415A (ja) 2019-07-18
IL264178B2 (en) 2024-05-01
ZA201900317B (en) 2022-10-26
US20190382367A1 (en) 2019-12-19
CN109715612A (zh) 2019-05-03
US20200190053A1 (en) 2020-06-18
US10597377B2 (en) 2020-03-24
CN109715612B (zh) 2022-09-16
JP6967577B2 (ja) 2021-11-17
KR20190026914A (ko) 2019-03-13
TWI789355B (zh) 2023-01-11
HUE060182T2 (hu) 2023-02-28
US20190002431A1 (en) 2019-01-03
AU2020277122A1 (en) 2020-12-24
EP3484865A1 (en) 2019-05-22
US9896432B2 (en) 2018-02-20
EP4163276A1 (en) 2023-04-12
IL264178A (en) 2019-02-28
WO2018013676A1 (en) 2018-01-18
US10875839B2 (en) 2020-12-29
US20260008767A1 (en) 2026-01-08
DK3484865T3 (da) 2022-10-31
EP3484865B1 (en) 2022-09-14
IL264178B1 (en) 2024-01-01
US20220380337A1 (en) 2022-12-01
US11414397B2 (en) 2022-08-16
PT3484865T (pt) 2022-11-03
CN115557929A (zh) 2023-01-03
SMT202200465T1 (it) 2023-01-13
AU2017296392B2 (en) 2020-09-24
KR20210134838A (ko) 2021-11-10
US20210171492A1 (en) 2021-06-10
EP3484865A4 (en) 2019-12-25
KR102324042B1 (ko) 2021-11-09
BR112019000692A8 (pt) 2022-03-03
ES2931472T3 (es) 2022-12-29
MX2019000588A (es) 2019-09-09
AU2017296392A1 (en) 2019-02-28
NZ750174A (en) 2023-04-28
SG11201900349VA (en) 2019-02-27
PL3484865T3 (pl) 2023-01-09
RS63776B1 (sr) 2022-12-30

Similar Documents

Publication Publication Date Title
FIC20230014I1 (fi) Foslevodopa ja foskarbidopa
IL285286A (en) Transposase polypeptides and uses thereof
HUE060182T2 (hu) Szomatosztatin modulátorok és azok felhasználása
IL248979B (en) Syntac polypeptides and uses thereof
FI3494134T3 (fi) Muunneltuja polypeptidejä ja niiden käyttötapoja
LT3448386T (lt) Izochinolin-3-ilo karboksamidai ir jų gamyba bei naudojimas
LT3368534T (lt) Valbenazino ditozilatas ir jo polimorfai
LT3317284T (lt) Benzoksazepino oksazolidinono junginiai ir jų naudojimo būdai
DK3212255T3 (da) Selvorienterende sprøjte og sprøjtegrænseflade
DK3227342T3 (da) Proteinøs heterodimer og anvendelse deraf
LT3333191T (lt) Anti-c10orf54 antikūnai ir jų panaudojimas
LT3412302T (lt) Modifikuoti fgf-21 polipeptidai ir jų panaudojimai
LT3280441T (lt) Anti-sortilino antikūnai ir jų naudojimo būdai
EP3205103C0 (en) INTER AND INTRA UNIFICATION BLOCK COPY
LT3215532T (lt) Anti-tim3 antikūnai ir jų naudojimo būdai
EP4135127C0 (en) MICRO-ASSEMBLY STRATEGIES AND DEVICES FOR COMPOUNDS
LT3394065T (lt) Tetrahidropiranilamino-pirolopirimidinonas ir jo panaudojimo būdai
LT3099717T (lt) Antikūno molekulės tim-3-čiam ir jų panaudojimas
MA40933A (fr) Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines
LT3105253T (lt) Antikūnai prieš jagged1 ir jų naudojimo būdai
LT3102555T (lt) Junginių kompozicijos ir jų panaudojimas
LT3319612T (lt) Oksisteroliai ir jų naudojimo būdai
DK3161139T3 (da) Tlr-4-specifikke aptamerer og anvendelser heraf
LT3498292T (lt) Uspa2 baltymo konstruktai ir jų panaudojimas
LT3672948T (lt) Piridinamino-piridono ir pirimidinamino-piridono junginiai